Oxford Biomedica (LON:OXB) Hits New 1-Year High - What's Next?

Key Points

• Oxford Biomedica's stock reached a new 52-week high at GBX 618 ($8.33) during trading, reflecting a significant increase from its previous close of GBX 586.71 ($7.90).
• Analysts have mixed opinions on the stock, with a consensus rating of "Moderate Buy" and a target price averaging GBX 540.25, while some brokerages have set differing price targets between GBX 400 and GBX 930.
• Insider transactions included the purchase of 67,000 shares by Roch Doliveux for £301,500, while Dame Kay Davies sold 4,563 shares for £22,815, indicating active insider involvement.

Oxford Biomedica plc (LON:OXB - Get Free Report)'s stock price reached a new 52-week high during trading on Monday . The stock traded as high as GBX 618 ($8.35) and last traded at GBX 617 ($8.34), with a volume of 922845 shares trading hands. The stock had previously closed at GBX 586.71 ($7.93).

Analyst Ratings Changes

Several brokerages have recently issued reports on OXB. Peel Hunt reiterated a "buy" rating and set a GBX 451 price objective on shares of Oxford Biomedica in a research report on Friday, August 1st. JPMorgan Chase & Co. reduced their target price on shares of Oxford Biomedica from GBX 490 to GBX 400 and set a "neutral" rating for the company in a research note on Tuesday, July 15th. Finally, Royal Bank Of Canada raised their price objective on shares of Oxford Biomedica from GBX 800 to GBX 930 and gave the stock an "outperform" rating in a report on Tuesday, August 26th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of GBX 540.25.

Oxford Biomedica Trading Up 7.4%

The firm's fifty day moving average is GBX 496.84 and its two-hundred day moving average is GBX 372.19. The company has a debt-to-equity ratio of 166.48, a current ratio of 2.35 and a quick ratio of 1.67. The firm has a market capitalization of £757.14 million, a PE ratio of -1,508.98 and a beta of 1.09.

Insider Activity

In other Oxford Biomedica news, insider Roch Doliveux acquired 67,000 shares of the stock in a transaction that occurred on Friday, August 15th. The stock was bought at an average cost of GBX 450 per share, with a total value of £301,500. Also, insider Dame Kay Davies sold 4,563 shares of the stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of GBX 500, for a total transaction of £22,815. Corporate insiders own 43.30% of the company's stock.

About Oxford Biomedica

Oxford Biomedica LSE: OXB is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.